Antileukemic potential of PEGylated gold nanoparticle conjugated with protein toxin (NKCT1) isolated from Indian cobra (Naja kaouthia) venom

Limited efficacy of current first-line treatment for leukemia calls attention for further development of efficient strategies. Recently, much attention has been given to nanoparticle-based drug delivery systems loaded with dual drugs to improve current disease therapies by overcoming toxicity. In the present study, we document to explore an approach to conjugate gold nanoparticles (GNPs) with protein toxin (NKCT1), a protein toxin from the Indian cobra (Naja kaouthia) venom, and to establish its antileukemic activity. GNP was prepared by NaBH4 reduction method. UV–vis spectroscopy of GNP showed the absorbance at 530 nm for plasma resonance. Dynamic light scattering (DLS) size of GNPs was 2–8 nm and the GNP-NKCT1 was 68–122 nm. CD spectra of GNP-NKCT1 showed change in percentage of β-turn as compared with NKCT1. GNP-NKCT1 significantly inhibited leukemic cell growth in dose- and time-dependent manner by two- to threefold more than NKCT1. For human leukemic lymphoma cell line and human myelogenous leukemic cell line, the IC50 dose was found to be 1.2 and 0.75 μg/ml, respectively, observed by trypan blue exclusion method and tetrazolium bromide reduction assay. Flow cytometric analysis showed appreciable number of both cell lines in early and late apoptotic stages and arrested cell cycle in the G1 phase by GNP-NKCT1. Resilient power of leukemic cell line after wound healing and migration or invasive power of the cell line was significantly low in GNP-NKCT1-treated plate than the control plate. These analyses reveal that GNP-NKCT1 possesses significant and selective anticancer activity, likely by inducing programmed cell death through mitochondrial and/or lysosomal pathway.


Introduction
Snake venoms contain a wide range of proteins and peptides (90-95 %), amino acids, nucleotides, free lipids, carbohydrates, and metallic elements bound to proteins (5 %). Snake venoms contain a large number of biologically active proteins and peptides that are usually similar in structure but not identical to that of prey physiological systems (de Lima et al. 2005;Heise et al. 1995;Tu 1988).
After discovery of "anticancer" activity of snake venom (Naja sp.) by Calmette et al. (1933), a number of studies has been carried out on anticancer activity on venom (Gomes et al. 2007;Zhang and Cui 2007;Chiu et al. 2009). Cancer, despite of the all-out efforts from developed countries still causes one in five deaths. Surgery, chemotherapy, and radiotherapy provide inadequate protection and instead affect normal cells along with cancer cells. The search for cancer cure from natural product (plants and animals) has been practiced for over a century and the use of purified chemicals to treat cancer still continues. From the 1940s to 2007, of the 155 new cytotoxic molecules developed, 47 % are actually either natural product or directly derived from them. Several studies have been undertaken during last three decades to establish the anticancer property of venoms and toxins . These lead to the discovery of several promising molecule having anticancer activity, some of which are in clinical trial and may emerged to be a future drug in cancer therapy. In our earlier studies, we have established the anticancer/cytotoxic effect of a lethal protein toxin NK-CT1 present in Indian monocellate cobra, Naja kaouthia (Debnath et al. 2010). Recently, Biswas et al. reviewed potential venoms and toxins along with nanoparticleconjugated venom toxins of snake, amphibians, and bees, etc for possible therapeutic clues against emerging disease (Biswas et al. 2012). The present study reports the increasing efficiencies of anticancer/cytotoxic activity of protein toxin NK-CT1 conjugating with gold nanoparticles.
Present-day nanomedicine exploits carefully a broad variety of structured nanoparticles. These nanoparticles may serve as diagnostic and therapeutic antiviral, antitumor, or anticancer agents (Faraji et al. 2009;Ghosh et al. 2008;Hu and Zhang 2012;Tiwari et al. 2011). The determinant success in therapeutic and diagnostic use of nanoparticle (NP) is the ability to deliver them to desired target. In this sense, NP can be conjugated with biological molecules to make them recognize the biological target. From the point of view of molecular recognition, proteins have a number of properties participating in ligand-receptor and protein-protein molecular interactions. Gold is used for nanoparticle applications because it is unreactive and is not sensitive to air or light. However, gold does like to form bonds with itself and for this reason their surfaces have to be covered with a layer of protective molecules, for example polyethylene glycol (PEG). Capping GNP with PEG could increase stability and biocompatibility. The aim of this work was to explore the conjugation of protein toxin (NKCT1) on GNP surface and characterization of GNP-NKCT1 and their stability. The purpose was to increase the anticancer activity of GNP-NKCT1 from the native protein toxin NKCT1.
2.2 Purification of protein toxin NKCT1 NKCT1 protein toxin was purified by ion-exchange column chromatography using CM cellulose and further purified by high-performance liquid chromatography (HPLC; Debnath et al. 2010). The fraction was desalted and concentrated by Centricon (Millipore MWCO 3 k). Purified NKCT1 was checked by SDS-polyacrylamide gel electrophoresis (PAGE) gel electrophoresis method (Laemmli 1970).

Synthesis of gold nanoparticles and conjugation of NKCT1
The gold nanoparticles were prepared by sodium borohydride reduction method (Samal et al. 2010) with modifications. The synthetic method developed for this experiment consistently produces stable gold nanoparticles provided the conditions are properly controlled. A 25 ml conical was well washed with aqua regia and dried. HAuCl4 (20 mM) and PEG (10 mg/ml) were mixed with sterile phosphate buffer (Liu et al. 2007). Then 100 mM NaBH 4 was added dropwise into the conical which was placed on magnetic stirrer at 37°C for 1 h (pH 7.2). Just after mixing the NaBH 4 , the color of the reaction mixture was light violet and after several minutes, it changed to deep blue. After 1 h of stirring, mixture is centrifuged at 8,000 rpm for 30 min. Pellet containing large nanoparticles was discarded and 1 mg/ml of protein toxin NKCT1 was added into the supernatant and suspension was kept at room 37°C for proper conjugation (Table 1).

Structural characterization of GNP-NKCT1
Conjugation was confirmed by running the 12 % PAGE gel electrophoresis along with low-range molecular marker. CD spectroscopy of the NKCT1 and GNP-NKCT1 was done using Jasco J-815 Circular Dichromism spectrometer with a 0.1-cm cuvette at 25°C for determination of change in secondary structure of native protein toxin upon its conjugation (Liu et al. 2007;Higuchi et al. 2007).

Biophysical characterisation of GNP-NKCT1
UV-vis spectroscopy (Perkin Elmer, Lambda-25) measurements from 200 to 700 nm and 400 to 700 nm were performed for NKCT1, GNP-NKCT1, and GNPs only. Spectra were taken at room temperature with 1 cm optical length cuvette with special resolution of 1 nm (Sobczak-Kupiec et al. 2011;Bhattacharya and Srivastava 2003;Olmedo et al. 2008;Sau et al. 2001;Zubarev et al. 2006). Dynamic light scattering measurements were performed in a Malvern Zetasizer Nano ZS apparatus (Malvern Instruments, Milan, Italy) at 25°C and started 2 min after the cuvette was placed in the dynamic light scattering (DLS) apparatus to allow the temperature to equilibrate. Measurement was carried out 24 h after the preparation of conjugation (Sobczak-Kupiec et al. 2011). The TEM image was obtained on a JEOL JSM 1100 transmission electron microscope. A drop of sample solution was allowed to dry on copper grid overnight (Sau et al. 2001;Zubarev et al. 2006). Atomic force microscope (AFM) image was taken using Atomic Force Microscope (Park System, XE-70, South Korea) in a dark room at 25°C in noncontact mode for confirmation of nanoparticle and conjugate size (Abdullin et al. 2009).

Separation and culture of normal lymphocytes
Blood was collected aseptically from the vein of healthy adults (aged 24-30), after informed consent, and transferred to heparinised vial. Lymphocytes were collected from whole blood using Ficoll histopaque after proper dilution with autoclaved saline water (Giri et al. 2006). Then, it was washed with 1× phosphate-buffered saline (PBS) and cultured in sterile complete RPMI 1640 media. Cells were grown in a CO 2 incubator at 37°C with 5 % CO 2 in humidified condition. The experiment was approved by the institutional human ethical committee (Ref. No. IHEC/AG/HUM/P17/12).
2.8 IC 50 dose determination of GNP-NKCT1 2.8.1 Cell growth inhibition studies on leukemic cells and normal lymphocytes U937, K562 (1 × 10 6 ) were seeded in 96-well sterile plates and were treated with different concentrations (1-5 μg/ml for U937 cell and 0.5-2 μg/ml for K562 cell of GNP-NKCT1 (I, II, and III)) for 24 and 48 h of incubation. Normal lymphocytes (1 × 10 6 ) were also seeded on 96-well and treated with IC 50 dose of cell lines with respect to standard drug imatinib mesylate (10 μg/ml). The cell growth inhibition studies were done using 0.2 % trypan blue with direct count under light microscope (Olympus, Tokyo) using hemocytometer chamber (Debnath et al. 2010).

Cytotoxicity studies on leukemic cells and normal lymphocytes
Exponentially growing U937 and K562 cells and freshly collected normal lymphocytes at a cell density of 1×10 6 /ml were incubated with different concentrations (1-5 μg/ml for U937 cell and 0.5-2 μg/ml for K562 cell IC 50 dose of both cell line and imatinib mesylate (10 μg/ml for normal lymphocytes)) of GNP-NKCT1 (I, II, and III) for 24 and 48 h at culturable conditions at CO 2 incubator. MTT assay of treated cells were done to confirm its cytotoxic effect (Sargent and Taylor 1989). Of the MTT solution, 40 μl (5 mg/ml) was added 4 h prior to the end of 24 and 48 h of incubation. The formazan granules formed by viable cells were dissolved in DMSO and the absorbance at 570 nm was estimated by measuring with an ELISA reader (BioTek, ELx800).

2.9
Morphological studies for detection of apoptosis 2.9.1 Florescence microscope studies U937 and K562 cells (1×10 6 ) treated with IC 50 dose of GNP-NKCT1 (respective of two cell lines) for 24 h were observed using a fluorescence microscope for morphological changes. The untreated control cells and the GNP-NKCT1-treated cells were harvested separately, washed with PBS, and then stained with acridine orange (100 μg/ml) and ethidium bromide (100 μg/ml, 1:1; Das et al. 2011). The cells were then immediately mounted on slides and observed under fluorescence microscope (Motic Image plus 2.0 software) for determination of the cells undergoing apoptosis.

Confocal microscopic studies
Leukemic cells (1×10 6 ) were treated with IC 50 dose of GNP-NKCT1 for 24 h. After 24 h, the untreated control and treated cells were pulled out and washed with ice-cold PBS. The cell was then stained with 10 μg/ml ethidium bromide and 5 μg/ml of 4′,6-diamidino-2-phenylindole (DAPI), respectively, on Llysine-coated slide for 5 min (Roy et al. 2008). After mounting on slides, the cells were observed to show the differences in nuclear morphology between the untreated and GNP-NKCT1-treated cells under confocal laser scanning microscope (Leica TCS-SP2 system). Image for ethidium bromide and DAPI were acquired from argon/krypton laser and UV laser line using 590 nm long-pass filter for ethidium bromide, 488 nm long-pass filter for DAPI, and 450 nm bandpass filter for UV images.

Wound-healing assay
Cells were grown to 99 % confluence in six-well plate at 37°C of 5 % CO2 incubator. A wound was created by scratching cells in 1.5-cm zone with sterile 200-μl pipette tip after the old medium was washed out. Then, cells were incubated in newly added sterile medium in the absence or presence of GNP-NKCT1 for 24, 48, and 72 h. Cell migration into wound surface was determined under an inverted microscope (Labomed, India).
2.11 Detection of apoptosis by DNA fragmentation and agarose gel electrophoresis U937 and K562 cells (1×10 6 ) were treated with IC 50 dose of GNP-NKCT1 for 24 h. The cells were harvested and washed twice with PBS. The cells were resuspended in 1 ml of digestion buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, and 0.5 % SDS), 100 μg ml −1 of proteinase K was added and incubation was done at 65°C water bath overnight. DNA extraction was done by following the general phenol-chloroform extraction procedure. After centrifugation, the upper layer was mixed with the same volume of isoamyl alcohol. Again after centrifugation, DNA precipitates were washed with 70 % ethanol, dried, and evaporated at room temperature and dissolved in TE buffer (pH 8.0) at 4°C overnight. To detect DNA fragments, the isolated DNA samples were electrophoresed overnight at 20 V in 1 % agarose gel and stained with ethidium bromide (Roy et al. 2008). DNA fragmentation was observed in UV transilluminator.

Detection of apoptosis by flow cytometric analysis
In order to investigate the type of cell death induced by GNP-NKCT1, flow cytometric analysis was done by performing dot plot assay (Debnath et al. 2010 (Ross et al. 2003). After mixing gently, it was kept for 20 min at room temperature in the dark. After centrifugation at 1,000 rpm for 5 min, 500 μl of PBS was dissolved and added to 10 μl (50 μg/ml) of PI staining solution and incubated for 15 min at room temperature in the dark. Then, the sample was analyzed with FACS verse (BD Bioscience).

Statistical analysis
All values are represented as arithmetic mean±SEM. Statistical analysis was done by Student's t test. A probability value of less than 0.05 was chosen as the criterion of statistical significance.

Purification of NKCT1
As previously reported by Debnath et al., NKCT1 was purified by ion-exchange method and 3.24 mg/ml protein was estimated by Lowry's method (Lowry et al. 1951).
HPLC showed only a single peak with a retention time of 10 min. SDS-PAGE showed single band with molecular weight of 6.7 kDa (Fig. 1a).

Conjugation of GNP with protein toxin NKCT1
Polyacrylamide gel electrophoresis of GNP-NKCT1 showed two bands as compared with the single band of NK-CT1. Molecular weight of the two bands of GNP-NKCT1 was found to be 10 and 14 kD, respectively (Fig. 1a), unconjugated NK-CT1 (above 4-5 %) was present and produced faint band in PAGE. CD spectra showed, native NK-CT1 contained 23 % α-helix, 19 % β-sheet, and 35 % random coil and GNP-NKCT1 contained 43.5 % α-helix, 24. 5 % β-sheet, and 32 % β-turn. Percent change after conjugation was found to be 20.5 % of α-helix, 5.5 % β-sheet. Found in the secondary structure of GNP-NKCT1, 32 % of β-turn Arrow indicates protein core around the GNP. Actual size of gold nanoparticle measured by atomic force microscope.
Where only GNP showed 5-25 nm (c), GNP-NKCT1 showed 40-220 nm (d) was found in the secondary structure of GNP-NKCT1 as compared with the 35 % random coil of NK-CT1. This data confirmed that cysteine/amide residue (Dolati et al. 2011) of the amino acid chain was conjugated with gold nanoparticle directly with the surface or via PEG attached with the GNP surface ( Fig. 1b and c).

Biophysical characterization of GNP-NKCT1
The gold nanoparticle formed was light violet/pink color having plasmon resonance at 530 nm (Fig. 2a). The plasmon resonance of GNP-NKCT1 was formed at the 528 and 220 nm, as compared with the plasmon resonance of NKCT1 which was at 220 nm ( Fig. 2b and c). The hydrodynamic diameter of the nanoparticle measurement with DLS was found in the range of 2-8 nm, with an average size of 4 nm (Fig. 2d). GNP-NKCT1 diameter was 68-122 nm, with an average size of 92 nm (Fig. 2e). Figure 3 shows highresolution TEM micrograph (HR-TEM) of bare GNP and NKCT1-coated GNP (Fig. 3a, b). The presence of layer around the nanoparticle core was due to NKCT1, which was observed by uranyl acetate staining. As observed, the PEG and one/two protein molecule covered the whole surface of the nanoparticle and increased the hydrodynamic size  of NKCT1-capped gold nanoparticle. AFM showed the cluster of the gold nanoparticle size and it was found to be 4-25 nm whereas with protein core, it was 45-225 nm (Fig. 3c, d). When normal human lymphocytes were treated with GNP-NKCT1 (1.2 μg/ml) for 48 h, there was 15-16 % decrease in count as compared to untreated control ( Fig. 4i-j). But when normal human lymphocyte were treated with standard drug imatinib mesylate (10 μg/ml) for 24 h, there was 34-35 % decrease in count ( Fig. 4i-j). This showed that cell death after GNP-NKCT1 treatment was significantly less in case of normal lymphocytes as compared to treated leukemic cells and also in comparison to the standard imatinib mesylate, toxicity of GNP-NKCT1 towards normal cells is less. The other two conjugated product, GNP-NKCT1 (1) and GNP-NKCT1 (2) did not show promising result. In U937 cells, IC 50 dose were 3.0 and 2.8 μg/ml, respectively, for GNP-NKCT1-II and GNP-NKCT1-III, whereas in K562 cells IC 50 dose were 1 μg/ml and more than 1 μg/ml, respectively, for GNP-NKCT1-II and GNP-NKCT1-III (Table 2). As GNP-NKCT1-I showed very promising result, it was selected as an experimental sample for rest of the experiment and it was abbreviated GNP-NKCT1 only.

Morphological studies for detection of apoptosis
Morphological observations of treated cells from both the cell lines under fluorescent microscope showed intact nuclei in control cell that gave bright green fluorescence ( Fig. 5a and c) whereas treated cells showed intense orange-red fluorescence showing signs of apoptosis ( Fig. 5b and d). Confocal microscopes revealed chromatin disintegration and formation of apoptotic bodies (Fig. 5e, g, i, and k) whereas control cell showed intact cell (Fig. 5f, h, j, and l).

GNP-NKCT1 inhibited leukemic cell migration
As shown in Fig. 6, the cell migration was obviously inhibited by GNP-NKCT1 with time-dependent manner. Where control cell (absence of GNP-NKCT1) showed growth in wound zone within 24 h, the treated cell showed very little growth in scratching zone after 48 h. After 72 h, 95.80 % control U937 cells migrated in the wound zone but it was only 40. 88 % in treated U937 cell; in case of K562 cells where in 99. 10 % were filled, only 51.60 % were filled by treated cell.

Detection of apoptosis by DNA fragmentation and agarose gel electrophoresis
The gel pattern of DNA samples isolated from untreated control cell lines showed intact bands whereas the gel pattern of DNA samples isolated from GNP-NKCT1-treated U937 (Fig. 7a) and K562 cells (Fig. 7b) showed smeary band. So, the observations confirmed that the treatment with GNP-NKCT1 causes apoptosis in human leukemic cells.

Detection of apoptosis by flow cytometric analysis
In the flow cytometric analysis, lower left ( (Fig. 8c).

Study of cell cycle arrest by flow cytometric analysis
The flow cytometric analysis showed that when compared with that of the untreated control U937 cells and K562 cells, 24 h of GNP-NKCT1 (3/4 of IC 50 dose) treatment caused a progressive increase in the number of cells with 2N DNA content, indicating that the GNP-NKCT1 treatment inhibited the growth of U937 and k562 cells by cell cycle arrest in G1 phase. Where U937-treated cell showed 78.58 % G1+G0, 6. 84 % S, and 8.81 % G2+M (Fig. 8f), the control cell showed 48.88 % G1+G0, 40.80 % S, and 8.98 % G2+M (Fig. 8e) where k562 cells showed 62.47 % G1+G0, 31.62 % S, and 2. 98 % G2+ M (Fig. 8h), the control cell showed 35.84% G1+ G0, 50.03 % S, and 11.86 % G2+M (Fig. 8g). 3.10 Estimation of total DNA by Ki-67 antihuman antibody using FACS The flow cytometer detected, DNA content of control cells was much higher than the treated cell lines. In case of control, U937 cell showed 97.06 % dividing phase and control K562 cell showed 88.70 % (Fig. 9a and c), but in treated cell line dividing cell were 46.11 and 65.68 %, respectively ( Fig. 9b and d). This result proved that control cell showed more dividing phase (S phase and G2+ M phase) than treated cell line.

Estimation of replication cycle by BrdU incorporation using FACS
The immunofluorescent staining of incorporated bromodeoxy uridine (BrdU) and flow cytometry analysis provide a highresolution technique to determine the frequency and nature of individual cells that have synthesized DNA. In this method, BrdU (an analog of DNA precursor thymidine) is incorporated into newly synthesized DNA by cells entering and progressing through the S (DNA synthesis) phase of cell cycle. Often, staining with a dye that binds to total DNA such as 7-ADD is coupled with immunofluorescent BrdU staining. With this combination, two-color combination and two-color flow cytometry analysis permits the enumeration and characterization of cells that are actively synthesizing DNA in terms of their cell cycle position. BrdU incorporation via replication cycle (synthesis phase) was significantly decreased in GNP-NKCT1 treated cell with respect to control cell. Control U937 cell showed 54.04 % synthesis phase and GNP-NKCT1 treated cell showed 20.44 % ( Fig. 9e and f). In other set of experiment, GNP-NKCT1 treated K562 cell showed 50.7 % BrdU incorporation with respect to 71.04 % of BrdU in control K562 (Fig. 9g and h).

Discussions
The number of natural product-derived drugs present in the total drug launches from 1940 to 2011 was recently analyzed and it was concluded that natural products are still a significant source of new chemotherapeutic agent, especially anticancer (Newman et al. 2003). Although many chemotherapeutic drugs are used clinically, the overall survival of leukemia patients is far from satisfactory. Recent advances in nanotechnology have stimulated different applications in biomedicine where nanoparticles are used as drug delivery vehicles allowing rational manipulation of pharmacological profiles of drugs encapsulated in them and hence their concomitant therapeutic indices (Wang et al. 2009). The present investigation confirmed the increase of percentage of cytotoxicity activity and apoptosis against two human leukemic cell lines U937 and K562 including the conjugation of protein toxin NKCT1 with gold nanoparticle. Gold nanoparticle has special attraction to sulfur bond (Fan et al. 2003). Though protein toxin NKCT1 has cysteine residue, we used PEG for more stability of GNP-NKCT1. CD spectra showed the change in secondary structure that might be the bonding of N-terminal NH 2 or internal amide group of NKCT1 via the hydroxyl (OH) group of PEG with gold nanoparticle; still some work (i.e., FTIR, XPS, EELS) should be done to investigate the proper bonding of GNP with NKCT1 (Liu et al. 2007;Shi et al. 2004). UV-vis spectroscopy showed surface plasmon resonance at 520-540 nm which is the primary characteristics of gold nanoparticle formation (Triulzi et al. 2008). For using of strong reducing agent like sodium borohydrate for the preparation of GNP, it became very much polydisperse in size. The formation of GNPs by NaBH 4 and sodium citrate method was different. In sodium citrate method, after formation of GNPs, it became capped by citrate ion that is why they repelled each other and stayed single in solution. But in NaBH 4 method, they became as Au 0 state that is why they attracted each other and formed the cluster of GNPs with time-dependent manner.
Where HR-TEM confirmed the formation of various size of gold nanoparticle formation, PAGE gel electrophoresis showed molecular weight became 10 to 14 kDa which means one or two protein chains were conjugated per gold nanoparticle. The GNP-NKCT1 is stable at room temperature and showed the same efficiency effect after 1 month of storing at Fig. 5 (continued) room temperature (30 o ±5°C); GNP not only increases the life span of NKCT1. Our study emphasize on the already established fact that GNP-NKCT1 were taken up more by leukemic cell in comparison to native protein NKCT1. The lower uptake of native NKCT1 is attributed to the resistance experienced by them due to P-gp pump highly expressed on leukemia cells (Hui et al. 2008) which acts as an energy drug efflux pump and leads to decrease in cytotoxic protein accumulation. The nanoparticle conjugation system escapes the Pgp pump as their uptake is mediated by specific endocytic processes (Sahoo and Labhasetwar 2005). Thus, gold nanoparticle-conjugated NKCT1 preferentially delivered into the cells or subcellular organelle like mitochondria or lysosome for eliciting a better therapeutic effect than native protein NKCT1. The antiproliferative and the cytotoxic activities of GNP-NKCT1 were supported by observations in cell growth inhibition studies and in MTT assays, respectively. GNP-NKCT1 inhibited the growth and electron transport chain via blocking of succinate dehydrogenase in mitochondria of U937 and K562 cells in concentration-and time-dependent manner. In separate study, we saw GNP-NKCT1 possesses potent immunomodulatory activity and that concentrations (IC 50 dose of U937 cell) showed very less toxic effect on normal lymphocyte cell line as observed by trypan blue exclusion and MTT assay. This finding reveals that GNP-NKCT1 preferentially acts on leukemic cells. Competency of drug-loaded nanoparticles in inhibiting the growth of K562 cells were recently studied by Palma et al., where imatinib-loaded microcapsules were used to targeted leukemia stem cells more profoundly than native imatinib (Palma et al. 2010). Similar approach was also taken up by Luo et al. and Yang et al. who have used N succinyl chitosan nanoparticles and lipid nanoparticles on K562 cells for better antitumor effect (Luo et al. 2009;Yang et al. 2009). There are two main strategies by which chemotherapeutic agents are capable of exerting their effect: (1) is by induction of apoptosis and (2) is by cell cycle inhibition. Many of the compounds under study as antitumor agents act at multiple steps in cell cycle, and their effects may be cytostatic or cytotoxic, depending on the cell cycle status of the target cells (Shapiro and Harper 1999). In this context, our study indicated that at lower concentration (0.5 μg/ml for K562 cell line and 0. 9 μg/ml for U937 cell line) of GNP-NKCT1 was able to cause cell cycle arrest at particular phase while at a higher concentration (0.75 μg/ml for K562 cell line and 1. 2 μg/ml for U937 cell line) it was capable of inducing apoptosis. Central dogma of the cell was inhibited by the treatment of GNP-NKCT1. BrdU, which is the analog of the DNA precursor thymidine, is incorporated during the first major round of cell cycle activity. Flow cytometry detected inhibition of replication as treated    (Ghiringhelli et al. 2005). Protein expression on the nuclear surface became less as detected by ki-67, a nuclear proliferation associated antigen expressed in all active stages of the cell. After GNP-NKCT1 treatment, cell cycle arrest as well as Apoptosis is an important continuous and highly regulated cellular process resulting in destruction of undesirable cells during development or homeostasis in multicellular organisms (Kaufmann and Hengartner 2011). Apoptogenic activity of GNP-NKCT1 was investigated by different morphological studies like fluorescence microscopic, confocal microscopic, and phosphatidylserine externalization studies. The process of apoptosis is characterized by several morphological changes such as membrane blebbing, chromatin condensation, and nuclear fragmentation. Fluorescence microscopic image clearly showed nuclear disintegration of GNP-NKCT1-treated leukemic cells compared with control cell when stained with acridine orange and ethidium bromide. The control cells showed bright green fluorescence as the live cells with intact membrane excluded ethidium bromide and only acridine orange could enter into them. On the contrary, GNP-NKCT1treated cells showed more intense red fluorescence and reduced green fluorescence since apoptotic and necrotic cells could not exclude the dyes and gave a combination of orangered fluorescence. Apoptogenic activity of GNP-NKCT1 was further evidenced from the confocal microscopy images of treated leukemic cells when compared to control cell. After GNP-NKCT1, leukemic cell lines showed several signs of apoptosis like chromatin condensation and nuclear fragmentation whereas the untreated control cells were with intact nuclei. Externalization of PS from inner leaflet to outer leaflet of the membrane is the hallmark of apoptosis. Externally translocated PS bind with Annexin V in a calcium-dependent manner. Flow cytometry detected Annexin V-FITC and showed the dot plot supporting the fact that treatment with GNP-NKCT1-induced apoptosis in the leukemic cells. Cells undergoing apoptosis usually exhibited fragmentation of the cell into membranebound apoptotic bodies, nuclear and cytoplasmic condensation, and endolytic cleavage of the DNA into small oligonucleosomal fragments (Thatte et al. 2000). Further evidence in support of apoptogenic activity of GNP-NKCT1 was obtained from gel patterns of agarose gel electrophoresis. GNP-NKCT1 showed smeary bands, a typical indication of apoptosis whereas the untreated control cells showed intact DNA bands. Apoptosis is a tightly regulated process, which involves changes in expression of distinct set of genes. Two of the major genes responsible for regulating the mitochondrial apoptosis pathway are antiapoptic Bcl-2 and proapoptic bax (Tong et al. 2004). Debnath et al. reported that NKCT1-induced the apoptosis in leukemic cell line like U937 and K562 via activation of Bcl2: bax and cleaved PRAP levels with increasing dose of NKCT1. We also believed that our conjugated GNP-NKCT1 follow the same signaling pathway. Further work is going on molecular signaling.

Conclusion
This study exhibited that conjugation of gold nanoparticle with NKCT1 work in synergistic manner lowering both dose of administration and time of action of the NKCT1 ensuring that GNP release the NKCT1 to the target cell by controlled manner and two-to threefold increase the cytotoxic effect while minimizing the toxic effect of NKCT1. This conjugation was capable of showing high antileukemic activity by inducing cell cycle arrest and promoting apoptosis regulating activities like nuclear fragmentation. Moreover, regulation of various biochemical pathways after inhibiting the transcriptional and translational level by GNP-NKCT1 treatment supports the evolving concept that such nanoparticle conjugation may be helpful for leukemia therapy in the near future.